Company profile
RxSight, Inc.
NASDAQ: RXST · Healthcare · Medical - Devices
#321 of 1,420 Healthcare companies by revenue36th-percentile growth
EA Score
60CFH 63DQ 56GM 58SS 56
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, filing timeliness · ↓ listing tenure, Piotroski F
Methodology →Revenue TTM
$127.5M
Rev growth YoY (TTM)
-19.5%
Net income (FY)
-$38.9M
Employees
461
as of 2026-08-13
Market cap
$292.3M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$134.5M$134.5M2025
Net income-$38.9M-$38.9M2025
Operating income-$48.2M-$48.2M2025
Total assets$311.8M$311.8M2025
Liabilities$36.1M$36.1M2025
Equity$275.7M$275.7M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
RxLAL80%
L D D15%
Service Warranty Service Contracts And Accessories4%
By geography
Not disclosed.
The read
What is RxSight, Inc.’s revenue?
RxSight, Inc. booked $134.5M in FY2025 revenue, contracting 3.9% year over year — slower than 64% of Healthcare companies we track, at a -29.0% net margin.
Peers · Healthcare
Quanterix Corporation56CTelesis Bio, Inc.——National Research Corporation75B+Xtant Medical Holdings, Inc.74BUpHealth, Inc.——Niagen Bioscience Inc78B+Neighbors
Orange →Key facts
CEOAziz Mottiwala
SectorHealthcare
IndustryMedical - Devices
HeadquartersAliso Viejo, CA
ExchangeNASDAQ: RXST
Employees461
IPO date2021-07-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.